Antigenic Fingerprinting of Respiratory Syncytial Virus (RSV)-A-Infected Hematopoietic Cell Transplant Recipients Reveals Importance of Mucosal Anti-RSV G Antibodies in Control of RSV Infection in Humans

被引:14
作者
Fuentes, Sandra [1 ]
Hahn, Megan [1 ]
Chilcote, Katarina [1 ]
Chemaly, Roy F. [2 ]
Shah, Dimpy P. [3 ]
Ye, Xunyan [4 ]
Avadhanula, Vasanthi [4 ]
Piedra, Pedro A. [4 ,5 ]
Golding, Hana [1 ]
Khurana, Surender [1 ]
机构
[1] US FDA, Div Viral Prod, Ctr Biol Evaluat & Res, 10903 New Hampshire Ave, Silver Spring, MD 20993 USA
[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[3] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA
[4] Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA
[5] Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA
基金
美国国家卫生研究院;
关键词
RSV; mucosal immunity; antibody; immune response; HCT; antibody affinity; epitope; repertoire; infection; virus; FUSION GLYCOPROTEIN; VIRAL-INFECTIONS; PROTEIN; PROTECTION; VACCINE; IDENTIFICATION; CHALLENGE; IMMUNITY; DISEASES;
D O I
10.1093/infdis/jiz608
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. Respiratory syncytial virus (RSV) infection causes significant morbidity in hematopoietic cell transplant (HCT) recipients. However, antibody responses that correlate with recovery from RSV disease are not fully understood. Methods. In this study, antibody repertoire in paired serum and nasal wash samples from acutely RSV-A-infected HCT recipients who recovered early (<14 days of RSV shedding) were compared with late-recovered patients (>= 14 days of shedding) using gene fragment phage display libraries and surface plasmon resonance. Results. Anti-F serum responses were similar between these 2 groups for antibody repertoires, neutralization titers, anti-F binding antibodies (prefusion and postfusion proteins), antibody avidity, and binding to specific antigenic sites. In contrast, nasal washes from early-recovered individuals demonstrated higher binding to F peptide containing p27. While the serum RSV G antibody repertoires in the 2 groups were similar, the strongest difference between early-recovered and late-recovered patients was observed in the titers of nasal wash antibodies, especially binding to the central conserved domain. Most importantly, a significantly higher antibody affinity to RSV G was observed in nasal washes from early-recovered individuals compared with late-recovered HCT recipients. Conclusions. These findings highlight the importance of mucosal antibodies in resolution of RSV-A infection in the upper respiratory tract.
引用
收藏
页码:636 / 646
页数:11
相关论文
共 36 条
[21]   Characteristics of immunity induced by viral antigen or conferred by antibody via different administration routes [J].
Matsuoka, T ;
Okamoto, Y ;
Matsuzaki, Z ;
Endo, S ;
Ito, E ;
Tsutsumi, H ;
Williamson, RA ;
Sakurai, H ;
Burton, DR ;
Saito, I .
CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2002, 130 (03) :386-392
[22]   Neutralizing epitopes on the respiratory syncytial virus fusion glycoprotein [J].
McLellan, Jason S. .
CURRENT OPINION IN VIROLOGY, 2015, 11 :70-75
[23]   Structure-Based Design of a Fusion Glycoprotein Vaccine for Respiratory Syncytial Virus [J].
McLellan, Jason S. ;
Chen, Man ;
Joyce, M. Gordon ;
Sastry, Mallika ;
Stewart-Jones, Guillaume B. E. ;
Yang, Yongping ;
Zhang, Baoshan ;
Chen, Lei ;
Srivatsan, Sanjay ;
Zheng, Anqi ;
Zhou, Tongqing ;
Graepel, Kevin W. ;
Kumar, Azad ;
Moin, Syed ;
Boyington, Jeffrey C. ;
Chuang, Gwo-Yu ;
Soto, Cinque ;
Baxa, Ulrich ;
Bakker, Arjen Q. ;
Spits, Hergen ;
Beaumont, Tim ;
Zheng, Zizheng ;
Xia, Ningshao ;
Ko, Sung-Youl ;
Todd, John-Paul ;
Rao, Srinivas ;
Graham, Barney S. ;
Kwong, Peter D. .
SCIENCE, 2013, 342 (6158) :592-598
[24]   Structure of RSV Fusion Glycoprotein Trimer Bound to a Prefusion-Specific Neutralizing Antibody [J].
McLellan, Jason S. ;
Chen, Man ;
Leung, Sherman ;
Graepel, Kevin W. ;
Du, Xiulian ;
Yang, Yongping ;
Zhou, Tongqing ;
Baxa, Ulrich ;
Yasuda, Etsuko ;
Beaumont, Tim ;
Kumar, Azad ;
Modjarrad, Kayvon ;
Zheng, Zizheng ;
Zhao, Min ;
Xia, Ningshao ;
Kwong, Peter D. ;
Graham, Barney S. .
SCIENCE, 2013, 340 (6136) :1113-1117
[25]   Prefusion F-specific antibodies determine the magnitude of RSV neutralizing activity in human sera [J].
Ngwuta, Joan O. ;
Chen, Man ;
Modjarrad, Kayvon ;
Joyce, M. Gordon ;
Kanekiyo, Masaru ;
Kumar, Azad ;
Yassine, Hadi M. ;
Moin, Syed M. ;
Killikelly, April M. ;
Chuang, Gwo-Yu ;
Druz, Aliaksandr ;
Georgiev, Ivelin S. ;
Rundlet, Emily J. ;
Sastry, Mallika ;
Stewart-Jones, Guillaume B. E. ;
Yang, Yongping ;
Zhang, Baoshan ;
Nason, Martha C. ;
Capella, Cristina ;
Peeples, Mark E. ;
Ledgerwood, Julie E. ;
McLellan, Jason S. ;
Kwong, Peter D. ;
Graham, Barney S. .
SCIENCE TRANSLATIONAL MEDICINE, 2015, 7 (309)
[26]   Differential human antibody repertoires following Zika infection and the implications for serodiagnostics and disease outcome [J].
Rayichandran, Supriya ;
Hahn, Megan ;
Belaunzaran-Zamudio, Pablo F. ;
Ramos-Castaneda, Jose ;
Najera-Cancino, Gabriel ;
Caballero-Sosa, Sandra ;
Navarro-Fuentes, Karla R. ;
Ruiz-Palacios, Guillermo ;
Golding, Hana ;
Beigel, John H. ;
Khurana, Surender .
NATURE COMMUNICATIONS, 2019, 10 (1)
[27]   Changing epidemiology of respiratory viral infections in hematopoietic cell transplant recipients and solid organ transplant recipients [J].
Renaud, Christian ;
Campbell, Angela P. .
CURRENT OPINION IN INFECTIOUS DISEASES, 2011, 24 (04) :333-343
[28]   Impact of aerosolized ribavirin on mortality in 280 allogeneic haematopoietic stem cell transplant recipients with respiratory syncytial virus infections [J].
Shah, Dimpy P. ;
Ghantoji, Shashank S. ;
Shah, Jharna N. ;
El Taoum, Katia K. ;
Jiang, Ying ;
Popat, Uday ;
Hosing, Chitra ;
Rondon, Gabriela ;
Tarrand, Jeffrey J. ;
Champlin, Richard E. ;
Chemaly, Roy F. .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2013, 68 (08) :1872-1880
[29]  
Shah DP, 2012, AM J BLOOD RES, V2, P203
[30]   Passive and active immunization against respiratory syncytial virus for the young and old [J].
Villafana, Tonya ;
Falloon, Judith ;
Griffin, M. Pamela ;
Zhu, Qing ;
Esser, Mark T. .
EXPERT REVIEW OF VACCINES, 2017, 16 (07) :737-749